Polypills with or without aspirin for primary prevention of cardiovascular disease

Polypills with or without aspirin for primary prevention of cardiovascular disease

Détails bibliographiques
Auteurs principaux:	Mant, J, McManus, R
Format:	Journal article
Langue:	English
Publié:	Elsevier 2021

Documents similaires

Would primary healthcare professionals prescribe a polypill to manage cardiovascular risk? A qualitative interview study
par: Virdee, S, et autres
Publié: (2013)

Cost-effectiveness analysis of use of a polypill versus usual care or best practice for primary prevention in people at high risk of cardiovascular disease
par: Jowett, S, et autres
Publié: (2017)

Polypill for cardiovascular disease prevention.
par: Dalton, A
Publié: (2013)

Cost-effectiveness analysis of use of a polypill versus usual care or best practice for primary prevention in people at high risk of cardiovascular disease.
par: Sue Jowett, et autres
Publié: (2017-01-01)

The Concept of the Polypill in the Prevention of Cardiovascular Disease
par: Brandon Wiley, et autres
Publié: (2014-04-01)

Use of cardiovascular polypills for the secondary prevention of cerebrovascular disease
par: J. Masjuan, et autres
Publié: (2021-01-01)

Polypills for Primary Prevention of Cardiovascular Disease: A Systematic Review and Meta-Analysis
par: Omneya A. Kandil, et autres
Publié: (2022-04-01)

The feasibility of polypill for cardiovascular disease prevention in Asian Population
par: Apichard Sukonthasarn, et autres
Publié: (2021-03-01)

Missed opportunities in prevention of cardiovascular disease in primary care: a cross-sectional study.
par: Sheppard, J, et autres
Publié: (2014)

Benefits of the Polypill on Medication Adherence in the Primary and Secondary Prevention of Cardiovascular Disease: A Systematic Review
par: Lopez-Lopez JP, et autres
Publié: (2023-09-01)

A Polypill for primary prevention of cardiovascular disease: A feasibility study of the World Health Organization
par: Gunaratne Padma S, et autres
Publié: (2011-01-01)

Medicinal herbs: Potential polypills in cardiovascular diseases
par: Samaneh Noroozi, et autres
Publié: (2021-04-01)

Exercise Rehabilitation in Heart Disease: the real “polypill” for primary and secondary prevention
par: Massimo F. Piepoli
Publié: (2005-06-01)

The polypill: the solution for prevention of coronary heart disease?
par: Hendarto Natadidjaja
Publié: (2016-02-01)

Impact of age and sex on primary preventive treatment for cardiovascular disease in the West Midlands, UK: cross sectional study.
par: Sheppard, J, et autres
Publié: (2012)

THE ROLE OF POLYTABLETS (POLYPILL) IN THE TREATMENT OF CHRONIC CARDIOVASCULAR DISEASES
par: Николай Владимирович Абрамов, et autres
Publié: (2024-02-01)

Role of aspirin in primary prevention of cardiovascular disease
par: Patrono, C, et autres
Publié: (2019)

Aspirin overutilization for the primary prevention of cardiovascular disease
par: VanWormer JJ, et autres
Publié: (2014-12-01)

Aspirin for primary prevention of cardiovascular disease in diabetes
par: Ying Xing, et autres
Publié: (2019-07-01)

Polypill versus medication monotherapy in the prevention of cardiovascular diseases in Iran: An economic evaluation study
par: Ramin Ravangard, et autres
Publié: (2024-07-01)

Practical Decision Algorithms for the Use of the Cardiovascular Polypill in Secondary Prevention in Europe
par: Lilian Grigorian-Shamagian, et autres
Publié: (2021-08-01)

Maybe it's time for something a little different? The extent to which current pharmacotherapy practice conforms to national guidelines for primary for cardiovascular disease prevention
par: Sheppard, J, et autres
Publié: (2013)

The use of polypills in cardiovascular disease management: Benefits vs challenges
par: Yamaan Adil, et autres
Publié: (2024-09-01)

Cost-effectiveness of fixed-dose combination pill (Polypill) in primary and secondary prevention of cardiovascular disease: A systematic literature review.
par: Reza Jahangiri, et autres
Publié: (2022-01-01)

Aspirin and other antiplatelet agents in the secondary and primary prevention of cardiovascular disease.
par: Hennekens, C, et autres
Publié: (1989)

A Survey of Availability and Affordability of Polypills for Cardiovascular Disease in Selected Countries
par: Gautam Satheesh, et autres
Publié: (2024-07-01)

Misuse of Aspirin and Associated Factors for the Primary Prevention of Cardiovascular Disease
par: Yinong Chen, et autres
Publié: (2021-09-01)

Redefining the polypill: pros and cons in cardiovascular precision medicine
par: Siddharth Birla, et autres
Publié: (2023-09-01)

Which people should take aspirin for primary prevention of cardiovascular disease?
par: Lozano R, et autres
Publié: (2015-07-01)

Use and Misuse of Aspirin in Primary Cardiovascular Prevention
par: Sergio Coccheri
Publié: (2017-04-01)

Aspirin for prevention of cancer and cardiovascular disease.
par: Rose, P, et autres
Publié: (2011)

Correction: A Survey of Availability and Affordability of Polypills for Cardiovascular Disease in Selected Countries
par: Gautam Satheesh, et autres
Publié: (2024-08-01)

Role of aspirin in the primary prevention of cardiovascular disease in patients with hyperlipoproteinaemia(a)
par: Eleni Giannopoulou, et autres
Publié: (2024-12-01)

US population qualifying for aspirin use for primary prevention of cardiovascular disease
par: Athena L. Huang, et autres
Publié: (2024-06-01)

US POPULATION QUALIFYING FOR ASPIRIN USE FOR PRIMARY PREVENTION OF CARDIOVASCULAR DISEASE:
par: Athena L. Huang, MD, et autres
Publié: (2023-09-01)

Preventing the progression of climate change: one drug or polypill?
par: Hugh Montgomery
Publié: (2017-03-01)

Maybe it's time for something a little different? The extent to which current pharmacotherapy practice conforms to national guidelines for stroke and cardiovascular disease prevention
par: Sheppard, J, et autres
Publié: (2013)

Primary prevention of cardiovascular events in diabetes: is there a role for aspirin?
par: Price, H, et autres
Publié: (2009)

Polypill holds promise for people with chronic disease
par: Jacqui Wise
Publié: (2005-12-01)

Aspirin in the primary prevention of vascular disease Reply
par: Baigent, C, et autres
Publié: (2009)